Novo Nordisk A/S (NVO) Current Ratio: 0.80
Is Novo Nordisk A/S’s current ratio high or low?
Novo Nordisk A/S's current ratio of 0.80 is in line with its 5-year average of 0.84, around the middle of its 5-year range (0.74–0.94).
As of Wednesday, June 17, 2026. 3.90% above its 12-month average of 0.77.
NVO Current Ratio Chart
NVO Average Current Ratio Chart
NVO Current vs Average Current Ratio Chart
NVO Current Ratio Metrics
CURRENT RATIO
0.80
CURRENT RATIO AVG TTM
0.77
CURRENT RATIO AVG 3Y
0.81
CURRENT RATIO AVG 5Y
0.84
CURRENT RATIO AVG 10Y
1.01
CURRENT RATIO AVG 15Y
1.25
CURRENT RATIO AVG 20Y
1.47
CURRENT VS TTM AVG
+3.90%
CURRENT VS 3Y AVG
-1.54%
CURRENT VS 5Y AVG
-4.95%
CURRENT VS 10Y AVG
-20.65%
CURRENT VS 15Y AVG
-35.97%
CURRENT VS 20Y AVG
-45.54%
NVO Competitors' Current Ratio
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $193.39B | 0.80 | 0.77 | 0.81 | 0.84 |
| Amgen Inc. (AMGN)vs › | $187.59B | 1.14 | 1.20 | 1.36 | 1.48 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $175.64B | 1.89 | 1.77 | 1.69 | 1.74 |
| Gilead Sciences, Inc. (GILD)vs › | $158.06B | 1.68 | 1.64 | 1.50 | 1.45 |
| Abbott Laboratories (ABT)vs › | $157.84B | 1.58 | 1.63 | 1.63 | 1.68 |
| Pfizer Inc. (PFE)vs › | $148.41B | 1.16 | 1.17 | 1.11 | 1.20 |
| Intuitive Surgical, Inc. (ISRG)vs › | $145.70B | 4.87 | 4.47 | 4.53 | 5.01 |
| Danaher Corporation (DHR)vs › | $128.06B | 1.87 | 1.64 | 1.71 | 1.69 |
| CVS Health Corporation (CVS)vs › | $127.73B | 0.84 | 0.82 | 0.86 | 0.88 |
| Stryker Corporation (SYK)vs › | $115.45B | 1.89 | 1.92 | 1.76 | 1.86 |
Liquidity Analysis
Current Ratio
0.80
Quick Ratio
0.57
Novo Nordisk A/S Current Ratio Formula & Definition
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S Current Ratio FAQ
- What is the current ratio for Novo Nordisk A/S (NVO)?
- The current ratio for NVO stock is 0.80.
- Is Novo Nordisk A/S's current ratio high or low?
- Novo Nordisk A/S's current ratio of 0.80 is in line with its 5-year average of 0.84, around the middle of its 5-year range (0.74–0.94).
- What is the TTM average current ratio for Novo Nordisk A/S (NVO)?
- The TTM average current ratio for NVO stock is 0.77.
- What is the 3Y average current ratio for Novo Nordisk A/S (NVO)?
- The 3Y average current ratio for NVO stock is 0.81.
- What is the 5Y average current ratio for Novo Nordisk A/S (NVO)?
- The 5Y average current ratio for NVO stock is 0.84.
- What is the 10Y average current ratio for Novo Nordisk A/S (NVO)?
- The 10Y average current ratio for NVO stock is 1.01.
- What is the 15Y average current ratio for Novo Nordisk A/S (NVO)?
- The 15Y average current ratio for NVO stock is 1.25.
- What is the 20Y average current ratio for Novo Nordisk A/S (NVO)?
- The 20Y average current ratio for NVO stock is 1.47.
Novo Nordisk A/S Current Ratio History
| DATE | CURRENT RATIO |
|---|---|
| 2025-12-31 | 0.80 |
| 2024-12-31 | 0.74 |
| 2023-12-31 | 0.82 |
| 2022-12-31 | 0.89 |
| 2021-12-31 | 0.86 |
| 2020-12-31 | 0.94 |
| 2019-12-31 | 1.06 |
| 2018-12-31 | 1.09 |
| 2017-12-31 | 1.28 |
| 2016-12-31 | 1.26 |
| 2015-12-31 | 1.35 |
| 2014-12-31 | 1.37 |
| 2013-12-31 | 1.74 |
| 2012-12-31 | 1.86 |
| 2011-12-31 | 1.91 |
| 2010-12-31 | 2.02 |
| 2009-12-31 | 2.44 |
| 2008-12-31 | 2.24 |
| 2007-12-31 | 2.28 |
| 2006-12-31 | 2.05 |
| 2005-12-31 | 1.85 |
| 2004-12-31 | 2.44 |
| 2003-12-31 | 2.45 |
| 2002-12-31 | 2.31 |
| 2001-12-31 | 2.31 |
| 2000-12-31 | 1.95 |
| 1999-12-31 | 2.43 |
| 1998-12-31 | 2.38 |
| 1997-12-31 | 2.42 |
| 1996-12-31 | 2.65 |
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar